NeuroOne Medical Technologies Restates Q2 Financials Due to Revenue Recognition Error, Reaffirms FY2026 Guidance

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced Friday that it will restate its financial results for the quarter ended March 31, 2026, after discovering a revenue recognition error during a post-release review. The adjustment reduces previously reported revenue by approximately $0.5 million and increases net loss by roughly $0.3 million, but the company emphasized that its ongoing business and fiscal year 2026 revenue guidance remain unaffected.

The error stemmed from a customer order modification on product shipment at the end of the quarter. The restatement corrects a one-time revenue overstatement of about $0.5 million against initially reported revenue of $2.4 million. Gross profit was overstated by approximately $0.3 million, and operating loss and net loss were understated by the same amount. No prior periods were impacted.

“This one-time correction does not change our revenue projections for the year,” said Dave Rosa, CEO of NeuroOne. “Our operations remain strong, our growth strategy is unchanged, and we continue to anticipate product revenue for fiscal 2026 of at least $10.5 million.”

The company’s Audit Committee determined on May 21, 2026, that the unaudited condensed financial statements in the Form 10-Q filed on May 12, 2026, should no longer be relied upon. NeuroOne intends to file an amendment to the Form 10-Q within the next few weeks and has initiated measures to improve internal controls over financial reporting.

Despite the restatement, NeuroOne reaffirmed its product revenue guidance for fiscal year 2026 of at least $10.5 million. The company also noted that its cash position as of March 31, 2026, and its growth plans remain unchanged. NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.

Analysts suggest that while the restatement raises questions about internal controls, the relatively small size of the error and the company’s swift corrective actions may limit negative impact on investor confidence. The reaffirmed guidance indicates that management expects the underlying business to perform as projected. For more information, visit nmtc1.com.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is NeuroOne Medical Technologies Restates Q2 Financials Due to Revenue Recognition Error, Reaffirms FY2026 Guidance.

The post NeuroOne Medical Technologies Restates Q2 Financials Due to Revenue Recognition Error, Reaffirms FY2026 Guidance appeared first on citybuzz.